Safety issues with intravenous iron products in the management of anemia in chronic kidney disease

Clinical Medicine and Research

Volumn 6, Issue 3-4, 2008, Pages 93-102

  Hayat, Amir ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Anemia; Chronic kidney disease; Intravenous iron products; Safety

Indexed keywords

ALUMINUM; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; IRON; IRON DEXTRAN; METHYLPREDNISOLONE; PLACEBO; TRANSFERRIN; ANTIANEMIC AGENT; HEMOGLOBIN;

ACUTE KIDNEY FAILURE; ALBUMIN BLOOD LEVEL; ANAPHYLAXIS; ARTHRALGIA; BACTEREMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COGNITION; DELAYED HYPERSENSITIVITY; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GASTROINTESTINAL ABSORPTION; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNE RESPONSE; INTRAVASCULAR HEMOLYSIS; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE DAMAGE; LABORATORY DIAGNOSIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHYSICAL PERFORMANCE; PREVALENCE; PROTEINURIA; RESTLESS LEGS SYNDROME; REVIEW; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; THERMOREGULATION; TISSUE INJURY; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; VASCULITIS; CHRONIC DISEASE; DRUG EFFECT; FACTUAL DATABASE; KIDNEY DISEASE; METABOLISM; MORTALITY; SAFETY;

ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; DATABASES, FACTUAL; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; SAFETY;

EID: 65349182361     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2008.811     Document Type: Review

References (107)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (2 Suppl 1):S1-266.
2. U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005. Available at: http://www.usrds.org/adr.htm.
3. U.S. Renal Data System, USRDS 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, June 2000. Available at: http://www.usrds.org/ adr.htm
4. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2006;18:CD003967.
5. World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization, 1968.
6. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134.
7. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003;14: 2919-2925.
8. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-1936.
9. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
10. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000;20:345-349.
11. Righetti M, Ferrario GM, Milani S, Serbelloni P, Sessa A. A single centre study about the effects of HFR on anemia. G Ital Nefrol. 2004;21 (Suppl 30):S168-171.
12. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007;18:382-393.
13. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37 (Suppl 1):S182-238.
14. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530-538.
15. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-984.
16. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; Suppl 1:S4-8.
17. Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 2001;47:82-85.
18. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573-1578.
19. Fishbane S, Kalantar-Zadeh K, Nissenson AR. Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 2004;17:336-341.
20. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004;19:141-149.
21. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996;7:2654-2657.
22. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (Suppl 2):ii1-ii47.
23. KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47 (5 Suppl 3):S11-145.
24. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15 (Suppl 2):S93-98.
25. Agarwal R. Nonhematological benefits of iron. Am J Nephrol 2007;27:565-571.
26. Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48 (4 Suppl 2):S1-106.
27. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
28. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997;48:34-40.
29. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305.
30. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single-center comparative study. J Am Soc Nephrol 1998;9:664-668.
31. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 1999;69:S71-78.
32. Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial Int 2001;21 (Suppl 3):S231-235.
33. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, for the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68: 2846-2856.
34. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-454.
35. Paschen HW. Efficient anaemia treatment with large intravenous iron doses. Geburtshilfe Frauenheilkunde 1949;9:604-616.
36. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose Am J Kidney Dis 2001;38:988-991.
37. Hadnagy C, Márkus T, Szurkos I. Sideroblast content of the bone marrow at the end of pregnancy or 1st days of puerperium, respectively. Zentralbl Gynakol 1977;99: 1106-1107.
38. Hadnagy C, Andreicut S, Binder P. Geophagia sideropenica. Folia Haematol Int Mag Klin Morphol Blutforsch 1977;104:648-655.
39. McCurdy PR, Rath CE, Meerkrebs GE. Parenteral iron therapy: with special reference to a new preparation for intramuscular injection. N Engl J Med 1957;257:1147-1153.
40. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med 2007;357:93-94.
41. Marchasin S, Wallerstein RO. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 1964;23: 354-358.
42. Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy DW, Henry DH. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008;19: 833-834.
43. Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H. Clinical use of the total dose infusion of iron dextran. J Lab Clin Med 1988;111:566-570.
44. Auerbach M, Winchester J, Wahab A, Richards K, McGinley M, Hall F, Anderson J, Briefel G. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998;31:81-86.
45. Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med 1998;131:257-260.
46. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfusion Altern Transfusion Med 2007;9:37-42. doi: 10.1111/ j.1778-428X.2007.00050.x.
47. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980;243:1726-1731.
48. Chertow, GM, Mason, PD, Vaage-Nilsen, O, Ahlmén, J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19:1571-1575.
49. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.
50. Cavill I. Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol Dial Transplant 2003;18 (Suppl 8): viii24-viii28.
51. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG; Ferrlecit Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-1839.
52. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999;33:464-470.
53. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG; Ferlecit Investigators. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003;63:217-224.
54. Buus NH, Jensen JD. Severe intravascular haemolysis and acute renal failure following intravenous administration of iron dextran. Nephrol Dial Transplant 2007;22:661-662.
55. Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J, Rothstein M, Strom J, Wolfe A, Van Wyck D, Yee J; United States Iron Sucrose (Venofer) Clinical Trials Group. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004;66:1193-1198.
56. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American Clinical Trial. Am J Kidney Dis 2000;36:88-97.
57. Sheashaa H, El-Husseini A, Sabry A, Hassan N, Salem A, Khalil A, El-Agroudy A, Sobh M. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. Nephron Clin Pract 2005;99:c97-101.
58. Bielory L. Serum sickness from iron-dextran administration. Acta Haematol 1990;83:166-168.
59. Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O, Utas C. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007;29:423-426.
60. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfusion Altern Transfusion Med 2007;9:8-36. doi: 10.1111/j.1778-428X.2007.00042.x.
61. Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000;15: 1827-1834.
62. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Hörl WH, Sunder-Plassmann G. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003;14:2639-2644.
63. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9:655-663.
64. Ward CG, Hammond JS, Bullen JJ. Effect of iron compounds on antibacterial function of human polymorphs and plasma. Infect Immun 1986;51:723-730.
65. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995;10:377-381.
66. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9:869-876.
67. Seifert A, von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 1987;65:1015-1024.
68. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993;64:95-100.
69. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004;38:1090-1094.
70. Furuland H, Linde T, Ahlmén J, Christensson A, Strömbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-361.
71. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18:1272-1280.
72. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40: 90-103.
73. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32 (Suppl 1):42-49.
74. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T, Shasha SM, Kristal B. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003;18:924-930.
75. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62: 1524-1538.
76. Salahudeen AK, Oliver B, Bower JD, Roberts II LJ. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001;60:1525-1531.
77. Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G, Weninger M, Widness JA. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics 2001;107:78-85.
78. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 2000;95:2975-2982.
79. Knutson MD, Walter PB, Ames BN, Viteri FE. Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. J Nutr 2000;130:621-628.
80. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-2687.
81. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65:2279-2289.
82. Michelis R, Sela S, Kristal B. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels. Nephrol Dial Transplant 2005;20: 1963-1969.
83. Hussein S, Prieto J, O'Shea M, Hoffbrand AV, Baillod RA, Moorhead JF. Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J 1975;1:546-548.
84. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212-2217.
85. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981;304:319-324.
86. Eschbach Jr JW, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 1967;276: 653-658.
87. Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int 1989;36:1125-1132.
88. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6:24-29.
89. Powell LW, Jazwinska E, Halliday J. Changing concepts of haemochromatosis. Adv Exp Med Biol 1994;356:285-291.
90. Gokal R, Millard PR, Weatherall DJ, Callender ST, Ledingham JG, Oliver DO. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q J Med 1979;48:369-391.
91. Weiss G, Houston T, Kastner S, Jöhrer K, Grünewald K, Brock JH. Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood 1997;89:680-687.
92. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S; Krantz S; Lundin P; Nissenson A; Ogden D; Paganini E; Rader B; Rutsky E; Stivelman J. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
93. Cuthbert JA. Iron, HFE, and hemochromatosis update. J Invest Med 1997;45:518-529.
94. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004;66:144-156.
95. Sanai T, Oochi N, Okada M, Imamura K, Okuda S, Iida M. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats. J Lab Clin Med 2005;146:25-29.
96. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007;27:343-350.
97. Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528-530.
98. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (Suppl 2):ii1-ii47.
99. Case G. Maintaining iron balance with total-dose infusion of iron dextran. ANNA J 1998;25:65-68.
100. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products. Am J Nephrol 2000;20:455-462.
101. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;37:743-749.
102. Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;34:286-290.
103. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74-78.
104. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial. J Clin Oncol 2004;22:1301-1307.
105. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443-1449.
106. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anemia. Lancet 2007;369:1502-1504.
107. Bailie GR, Johnson CA, Mason NA. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000;35:1-12.